Introduction

This page provides a comprehensive analysis of the known insider trading history of Robert E Conway. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Robert E Conway has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALPN / Alpine Immune Sciences, Inc. Director 0
US:ABIO / ARCA biopharma, Inc. Director 50,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Robert E Conway. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Robert E Conway as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2024-05-20 2024-05-20 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock 		D - Sale to Issuer -50,000 0 -100.00
2022-01-04 2022-01-03 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (Right to buy) 		A - Award 10,000 10,000
2021-09-27 2021-09-23 4/A ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock 		P - Purchase 15,000 50,000 42.86 10.08 151,154 503,845
2021-09-24 2021-09-23 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock 		S - Sale 15,000 50,000 42.86 10.08 151,154 503,845
2021-09-23 2021-09-21 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock 		P - Purchase 10,000 35,000 40.00 9.80 97,966 342,881
2021-05-13 2021-05-12 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 10,000 50,000 25.00 3.19 31,947 159,735
2021-05-06 2021-05-05 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 10,000 40,000 33.33 3.23 32,345 129,380
2021-01-13 2021-01-12 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 12,000 12,000
2021-01-05 2021-01-04 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (Right to buy) 		A - Award 7,650 7,650
2020-12-21 2020-12-18 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 10,000 30,000 50.00 4.16 41,630 124,890
2020-11-23 2020-11-19 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Common Stock 		P - Purchase 10,000 25,000 66.67 8.03 80,300 200,750
2020-09-25 2020-09-25 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 5,000 20,000 33.33 4.28 21,400 85,598
2020-09-24 2020-09-22 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 3,056 15,000 25.59 4.66 14,241 69,898
2020-09-21 2020-09-21 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 10,000 11,944 514.40 4.77 47,660 56,925
2020-01-06 2020-01-02 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (Right to buy) 		A - Award 7,650 7,650
2019-01-04 2019-01-02 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (Right to buy) 		A - Award 7,650 7,650
2018-03-05 2018-03-01 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 8,000 8,000
2018-01-04 2018-01-02 4 ALPN ALPINE IMMUNE SCIENCES, INC.
Stock Option (Right to buy) 		A - Award 7,650 7,650
2017-07-17 2017-07-14 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 10,000 35,000 40.00 2.49 24,900 87,150
2017-05-11 2017-05-08 4 NVLS Nivalis Therapeutics, Inc.
Common Stock 		P - Purchase 15,000 60,000 33.33 2.28 34,200 136,800
2017-05-10 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock 		P - Purchase 5,000 45,000 12.50 2.34 11,700 105,300
2017-05-09 2017-05-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock 		P - Purchase 20,000 40,000 100.00 2.30 46,000 92,000
2017-05-08 2017-05-04 4 NVLS Nivalis Therapeutics, Inc.
Common Stock 		P - Purchase 10,000 20,000 100.00 2.26 22,600 45,200
2017-03-27 2017-03-24 4 ABIO ARCA biopharma, Inc.
Common Stock 		P - Purchase 25,000 25,000 2.59 64,750 64,750
2017-02-21 2017-02-16 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 8,000 8,000
2016-09-14 2016-09-12 4 NVLS Nivalis Therapeutics, Inc.
Stock Option (Right to Buy) 		A - Award 12,300 12,300
2016-02-16 2016-02-11 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 8,000 8,000
2015-12-11 2015-12-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock 		P - Purchase 10,000 10,000 8.10 81,000 81,000
2015-09-15 2015-09-11 4 NVLS Nivalis Therapeutics, Inc.
Stock Option (Right to Buy) 		A - Award 7,650 7,650
2015-07-20 2015-07-16 4 NVLS Nivalis Therapeutics, Inc.
Stock Option (Right to Buy) 		A - Award 11,475 11,475
2015-02-17 2015-02-12 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 8,000 8,000
2014-02-13 2014-02-11 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 8,000 8,000
2013-09-19 2013-09-17 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 2,608 2,608
2013-09-19 2013-09-17 4 ABIO ARCA biopharma, Inc.
Stock Option (right to buy) 		A - Award 14,750 14,750
2013-09-04 3 ABIO ARCA biopharma, Inc.
Common Stock 		0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)